<DOC>
	<DOC>NCT02564211</DOC>
	<brief_summary>This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy.</brief_summary>
	<brief_title>Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has Type 2 diabetes mellitus Has inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy Hemoglobin A1C (HbA1c) ≥7.0% and ≤10.0% before study participation History of type 1 diabetes mellitus or a history of ketoacidosis History of any of the following medications: Thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation, sodium glucose cotransporter 2 (SGLT2) inhibitors anytime Currently has a urinary tract infection or genital infection with subjective symptom</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>